Payment overview · 2025
General Payments
$126.36
8 reported records · 5 companies
Healthcare provider profile · identity verified
Christopher Morgan, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · STUTTGART, AR · NPI 1255397006
Verified facts
What the public records show
CMS Open Payments records show Christopher Morgan, M.D. received $126.36 in general payments during 2025 across 8 reported records.
Novo Nordisk Inc accounted for 23.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 114 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Tresiba as an associated drug or biological on 415 records involving 264 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Tresiba by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $29.90 | 23.7% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $29.15 | 23.1% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $28.82 | 22.8% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $20.22 | 16.0% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $18.27 | 14.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $126.36 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $29.90 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $29.90 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $29.15 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $28.82 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $20.22 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $18.27 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $18.27 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $14.26 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $13.50 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 44 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 114 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
16 | 14 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
114 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Tresiba open payments reported associated product |
CMS Open Payments — General Payments 415 supporting records · 264 recipient NPIs · example record 1188130328 |
Tresiba · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 1566 | 143 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1366 | 230 |
| Furosemide | Furosemide | 1190 | 139 |
| Amlodipine Besylate | Amlodipine Besylate | 1174 | 171 |
| Pantoprazole Sodium | Pantoprazole Sodium | 953 | 160 |
| Losartan Potassium | Losartan Potassium | 934 | 167 |
| Gabapentin | Gabapentin | 888 | 141 |
| Potassium Chloride | Potassium Chloride | 878 | 144 |
| Metoprolol Tartrate | Metoprolol Tartrate | 800 | 101 |
| Eliquis | Apixaban | 766 | 65 |
| Tamsulosin Hcl | Tamsulosin Hcl | 649 | 91 |
| Trazodone Hcl | Trazodone Hcl | 618 | 103 |
| Escitalopram Oxalate | Escitalopram Oxalate | 514 | 78 |
| Metoprolol Succinate | Metoprolol Succinate | 482 | 68 |
| Lisinopril | Lisinopril | 472 | 73 |
| Nifedipine Er | Nifedipine | 457 | 75 |
| Glipizide | Glipizide | 450 | 69 |
| Hydrochlorothiazide | Hydrochlorothiazide | 447 | 95 |
| Xarelto | Rivaroxaban | 410 | 34 |
| Meloxicam | Meloxicam | 389 | 104 |
| Sertraline Hcl | Sertraline Hcl | 389 | 57 |
| Clopidogrel | Clopidogrel Bisulfate | 388 | 57 |
| Metformin Hcl | Metformin Hcl | 386 | 67 |
| Citalopram Hbr | Citalopram Hydrobromide | 367 | 54 |
| Carvedilol | Carvedilol | 358 | 59 |
| Tramadol Hcl | Tramadol Hcl | 352 | 75 |
| Divalproex Sodium | Divalproex Sodium | 347 | 48 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 339 | 55 |
| Duloxetine Hcl | Duloxetine Hcl | 324 | 54 |
| Simvastatin | Simvastatin | 304 | 53 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 292 | 57 |
| Jardiance | Empagliflozin | 287 | 41 |
| Hydralazine Hcl | Hydralazine Hcl | 281 | 38 |
| Omeprazole | Omeprazole | 276 | 56 |
| Donepezil Hcl | Donepezil Hcl | 266 | 38 |
| Pregabalin | Pregabalin | 244 | 35 |
| Alendronate Sodium | Alendronate Sodium | 233 | 33 |
| Memantine Hcl | Memantine Hcl | 232 | 29 |
| Mirtazapine | Mirtazapine | 230 | 35 |
| Allopurinol | Allopurinol | 229 | 39 |
| Buspirone Hcl | Buspirone Hcl | 190 | 45 |
| Clonidine Hcl | Clonidine Hcl | 189 | 42 |
| Entresto | Sacubitril/Valsartan | 171 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 170 | 41 |
| Januvia | Sitagliptin Phosphate | 164 | 14 |
| Lorazepam | Lorazepam | 161 | 29 |
| Prednisone | Prednisone | 161 | 54 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 160 | 25 |
| Levetiracetam | Levetiracetam | 158 | 23 |
| Diclofenac Sodium | Diclofenac Sodium | 157 | 29 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 157 | 53 |
| Spironolactone | Spironolactone | 157 | 27 |
| Pravastatin Sodium | Pravastatin Sodium | 153 | 28 |
| Warfarin Sodium | Warfarin Sodium | 153 | 13 |
| Atenolol | Atenolol | 145 | 19 |
| Doxycycline Hyclate | Doxycycline Hyclate | 141 | 104 |
| Ropinirole Hcl | Ropinirole Hcl | 138 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 137 | 29 |
| Sucralfate | Sucralfate | 133 | 27 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 120 | 47 |
| Famotidine | Famotidine | 119 | 22 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 119 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 117 | 43 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 115 | 27 |
| Bupropion Xl | Bupropion Hcl | 114 | 18 |
| Finasteride | Finasteride | 114 | 21 |
| Ozempic | Semaglutide | 114 | 20 |
| Montelukast Sodium | Montelukast Sodium | 109 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 108 | 20 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 108 | 12 |
| Olanzapine | Olanzapine | 106 | 19 |
| Nebivolol Hcl | Nebivolol Hcl | 104 | 17 |
| Baclofen | Baclofen | 102 | 15 |
| Novolin R | Insulin Regular, Human | 101 | 16 |
| Paroxetine Hcl | Paroxetine Hcl | 99 | 15 |
| Celecoxib | Celecoxib | 96 | 25 |
| Alprazolam | Alprazolam | 95 | 26 |
| Temazepam | Temazepam | 94 | 17 |
| Ondansetron Odt | Ondansetron | 93 | 22 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 89 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 88 | 12 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 85 | 81 |
| Dicyclomine Hcl | Dicyclomine Hcl | 84 | 19 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 83 | 15 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 83 | suppressed |
| Topiramate | Topiramate | 82 | 15 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 79 | 53 |
| Glimepiride | Glimepiride | 75 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 74 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 74 | 15 |
| Bumetanide | Bumetanide | 74 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 73 | 26 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 69 | 11 |
| Labetalol Hcl | Labetalol Hcl | 69 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 69 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 67 | 16 |
| Ventolin Hfa | Albuterol Sulfate | 67 | 18 |
| Amiodarone Hcl | Amiodarone Hcl | 66 | 13 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 66 | 11 |
| Latanoprost | Latanoprost | 66 | 14 |
| Carbamazepine | Carbamazepine | 62 | suppressed |
| Primidone | Primidone | 60 | suppressed |
| Ibuprofen | Ibuprofen | 59 | suppressed |
| Levofloxacin | Levofloxacin | 59 | 38 |
| Fentanyl | Fentanyl | 58 | suppressed |
| Risperidone | Risperidone | 57 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 55 | 12 |
| Verapamil Er | Verapamil Hcl | 55 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 54 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 54 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 53 | suppressed |
| Estradiol | Estradiol | 52 | 12 |
| Benazepril Hcl | Benazepril Hcl | 50 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 49 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 49 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 48 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 48 | 34 |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 48 | suppressed |
| Myrbetriq | Mirabegron | 48 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 48 | suppressed |
| Valsartan | Valsartan | 48 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 47 | suppressed |
| Diazepam | Diazepam | 47 | suppressed |
| Fluconazole | Fluconazole | 47 | 34 |
| Propranolol Hcl | Propranolol Hcl | 47 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 46 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 46 | 13 |
| Gemtesa | Vibegron | 45 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 45 | 33 |
| Clonazepam | Clonazepam | 44 | 11 |
| Farxiga | Dapagliflozin Propanediol | 44 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 43 | suppressed |
| Linzess | Linaclotide | 43 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 42 | 12 |
| Solifenacin Succinate | Solifenacin Succinate | 42 | suppressed |
| Klor-Con M20 | Potassium Chloride | 40 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 40 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 40 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 40 | suppressed |
| Aripiprazole | Aripiprazole | 39 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 39 | 11 |
| Testosterone Cypionate | Testosterone Cypionate | 39 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 38 | 15 |
| Lansoprazole | Lansoprazole | 38 | suppressed |
| Azithromycin | Azithromycin | 37 | 33 |
| Divalproex Sodium Er | Divalproex Sodium | 37 | suppressed |
| Methocarbamol | Methocarbamol | 37 | suppressed |
| Clobazam | Clobazam | 36 | suppressed |
| Nystatin | Nystatin | 36 | 22 |
| Lactulose | Lactulose | 35 | suppressed |
| Metolazone | Metolazone | 35 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 34 | suppressed |
| Cephalexin | Cephalexin | 34 | 30 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 34 | 12 |
| Spiriva Respimat | Tiotropium Bromide | 34 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 32 | suppressed |
| Xifaxan | Rifaximin | 32 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 31 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 31 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 31 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 30 | 16 |
| Breo Ellipta | Fluticasone/Vilanterol | 30 | suppressed |
| Chlorthalidone | Chlorthalidone | 30 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 29 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 29 | suppressed |
| Irbesartan | Irbesartan | 29 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 29 | suppressed |
| Hydrocortisone | Hydrocortisone | 28 | suppressed |
| Timolol Maleate | Timolol Maleate | 28 | suppressed |
| Ketoconazole | Ketoconazole | 27 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 27 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 27 | suppressed |
| Humulin R | Insulin Regular, Human | 26 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 26 | suppressed |
| Fenofibrate | Fenofibrate | 25 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 25 | suppressed |
| Cefdinir | Cefdinir | 24 | 24 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 24 | suppressed |
| Insulin Lispro | Insulin Lispro | 24 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 24 | suppressed |
| Mupirocin | Mupirocin | 24 | 21 |
| Trimethoprim | Trimethoprim | 24 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 23 | suppressed |
| Amantadine | Amantadine Hcl | 23 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 23 | suppressed |
| Clozapine | Clozapine | 23 | suppressed |
| Levemir | Insulin Detemir | 23 | suppressed |
| Paliperidone Er | Paliperidone | 23 | suppressed |
| Synthroid | Levothyroxine Sodium | 23 | suppressed |
| Trulicity | Dulaglutide | 23 | suppressed |
| Nitroglycerin | Nitroglycerin | 22 | 16 |
| Tivicay | Dolutegravir Sodium | 22 | suppressed |
| Novolog | Insulin Aspart | 21 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 21 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 12 |
| Tradjenta | Linagliptin | 21 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 20 | suppressed |
| Fluticasone-Salmeterol Hfa | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Clonidine | Clonidine | 19 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 19 | suppressed |
| Ezetimibe | Ezetimibe | 19 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 17 |
| Budesonide | Budesonide | 18 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 18 | suppressed |
| Mexiletine Hcl | Mexiletine Hcl | 18 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 18 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 18 | 18 |
| Tresiba Flextouch U-100 | Insulin Degludec | 18 | suppressed |
| Colchicine | Colchicine | 17 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 17 | suppressed |
| Gemfibrozil | Gemfibrozil | 16 | suppressed |
| Mounjaro | Tirzepatide | 16 | suppressed |
| Ranolazine Er | Ranolazine | 16 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 16 | 14 |
| Calcitriol | Calcitriol | 15 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Methylprednisolone | Methylprednisolone | 15 | 13 |
| Premarin | Estrogens, Conjugated | 15 | suppressed |
| Torsemide | Torsemide | 15 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 14 | 11 |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 14 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 14 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 14 | suppressed |
| Methimazole | Methimazole | 14 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 14 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 14 | suppressed |
| Sotalol | Sotalol Hcl | 14 | suppressed |
| Telmisartan | Telmisartan | 14 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 14 | suppressed |
| Alphagan P | Brimonidine Tartrate | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 13 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 13 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 13 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 13 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 13 | 12 |
| Rizatriptan | Rizatriptan Benzoate | 13 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 13 | suppressed |
| Tresiba | Insulin Degludec | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Acetazolamide | Acetazolamide | 12 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 12 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 12 | suppressed |
| Galantamine Er | Galantamine Hbr | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 12 | suppressed |
| Miglitol | Miglitol | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Nyamyc | Nystatin | 12 | suppressed |
| Tamoxifen Citrate | Tamoxifen Citrate | 12 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 12 | suppressed |
| Admelog | Insulin Lispro | 11 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 11 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Haloperidol | Haloperidol | 11 | suppressed |
| Indomethacin | Indomethacin | 11 | suppressed |
| Invokana | Canagliflozin | 11 | suppressed |
| Misoprostol | Misoprostol | 11 | suppressed |
| Phenytoin | Phenytoin | 11 | suppressed |
| Zonisamide | Zonisamide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $126.36 · 8 records | Novo Nordisk Inc | AREXVY, FARXIGA, OTEZLA, Ozempic, QULIPTA, REPATHA, Rybelsus, TRELEGY ELLIPTA, UBRELVY | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error